Dado Ruvic/Reuters
Summary List Placement- Altimmune fell as much as 10% on Thursday after the FDA issued a clinical hold on the company's new drug application for AdCOVID, an intranasal COVID-19 vaccine candidate.
- Despite the clinical hold, Altimmune said it does not anticipate a significant impact to its clinical development timeline for the vaccine candidate.
- Visit Business Insider's homepage for more stories.
Altimmune, a clinical-stage biopharmaceutical company, fell as much as 10% on Thursday after the FDA issued a clinical hold on the company's COVID-19 vaccine candidate.
AdCOVID is a single-dose intranasal COVID-19 vaccine candidate in early stages of development by Altimmune. The FDA has requested certain protocol modifications and submission of additional chemistry, manufacturing and controls data.
Altimmune has responded to the FDA's clinical hold letter and at this point does not anticipate a significant impact to its overall development timeline for the vaccine candidate.
Altimmune has surged 557% year-to-date as of Wednesday's close as investors bid up potential COVID-19 vaccine developers.
Markets Insider
NOW WATCH: Warren Buffett lives in a modest house that's worth .001% of his total wealth
See Also:
- Short-seller Rob Majteles told us he was simply 'wrong early' on Tesla. He broke down why the bear case against the stock still stands, and warned the broader market is due an 'extraordinary reassessment.'
- Kevin Landis' high-growth tech fund has doubled investors' money this year. He told us 3 ways he put together a winning portfolio of 'head-scratchers' — including an unusual bet on electric cars.
- A fund manager at JPMorgan's $1.9 trillion asset management arm breaks down the 6 high-conviction bets he's making to stand out from the crowd next year — and shares the 2 biggest risks on his radar